MENT Enanthate (Trestolone Enanthate)
The enanthate ester of 7α-methyl-19-nortestosterone (MENT/trestolone), a long-acting injectable form of the Population Council's male-contraceptive androgen. About 10x more potent than testosterone, prostate-sparing, but strongly suppressive and progestogenic. The acetate is separately catalogued; this is the longer ester used off-label.
01 Overview
MENT (trestolone) is 7α-methyl-19-nortestosterone, developed by the Population Council as a candidate for male contraception and hypogonadism because it is roughly ten times as potent as testosterone, resists 5α-reduction (sparing the prostate), and delivers strong gonadotropin suppression. The enanthate ester extends its action for less frequent injection, in contrast to the short-acting acetate.
Human data exist mainly for the parent compound in contraceptive implant and injection studies; the enanthate ester itself is largely a grey-market / research preparation. Its potency and progestogenic, aromatisable nature make estrogen management and suppression the dominant practical issues.
02 Mechanism
Potent androgen receptor agonist; the 7α-methyl group blocks 5α-reduction (prostate-sparing) while the 19-nor backbone confers progestogenic activity and aromatisation to a potent estrogen. The enanthate ester is cleaved to release free MENT slowly.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal low | 25–50 mg/wk | IM | High potency means small doses; anecdotal only. |
| Anecdotal | 50–100 mg/wk | IM | No validated performance dosing. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| High-potency anabolismAnimal and receptor assays show potency roughly an order of magnitude above testosterone. | ~10x testosterone potency | Preclinical | |
| Prostate-sparing androgen actionResistance to 5α-reduction limits DHT-driven prostate growth relative to testosterone. | Reduced prostatic stimulation | Clinical | |
| Strong contraceptive suppressionIn contraceptive studies MENT suppressed spermatogenesis, especially combined with a progestin. | Azoospermia in trials | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Profound HPTA suppressionPotent, near-complete suppression of endogenous testosterone and spermatogenesis. | Severe | Universal | Clinical | |
| Estrogenic effectsAromatises to a potent estrogen, risking gynecomastia and water retention. | Moderate | Common | Preclinical |